Nektar Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1990-01-01

Employees: 137

Market Cap: $230M

Website: http://www.nektar.com

Introduction: Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Clinical Trials

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: LY3471851
Drug: Placebo

First Posted Date: 2018-06-14

Last Posted Date: 2023-11-18

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 48

Registration Number: NCT03556007

Locations: 🇺🇸
Investigator Site - Clearwater, Clearwater, Florida, United States
🇺🇸
Investigator Site - Great Neck, Great Neck, New York, United States
🇺🇸
Investigator Site - La Jolla, La Jolla, California, United States

and more 11 locations

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Merkel Cell Carcinoma
Triple Negative Breast Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Melanoma
Sarcoma
Renal Cell Carcinoma

Interventions: Drug: NKTR-262
Drug: bempegaldesleukin
Drug: nivolumab

First Posted Date: 2018-02-19

Last Posted Date: 2023-03-08

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 64

Registration Number: NCT03435640

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States

and more 11 locations

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: NKTR-214
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Atezolizumab
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2017-05-03

Last Posted Date: 2023-03-10

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 162

Registration Number: NCT03138889

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇪
Lungenklinik Hemer, Hemer, Germany
🇺🇸
Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States

and more 35 locations

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Phase 1

Completed

Conditions: Melanoma
Triple Negative Breast Cancer
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Urothelial Carcinoma
HR+/HER2- Breast Cancer
Gastric Cancer

First Posted Date: 2016-12-06

Last Posted Date: 2023-03-13

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 557

Registration Number: NCT02983045

Locations: 🇧🇪
CHU de Liège, Liège, Belgium
🇬🇧
Mount Vernon Cancer Centre, Northwood, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Withington, United Kingdom

and more 55 locations

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Phase 3

Completed

Conditions: Metastasis
Breast Cancer

Interventions: Drug: NKTR-102
Drug: Eribulin
Drug: Ixabepilone
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Docetaxel
Drug: Nab-paclitaxel

First Posted Date: 2016-09-27

Last Posted Date: 2023-04-14

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 178

Registration Number: NCT02915744

Locations: 🇺🇸
Investigator Site - Plantation, Plantation, Florida, United States
🇺🇸
Investigator Site - Boston, Boston, Massachusetts, United States
🇺🇸
Investigator Site - Columbus, Columbus, Ohio, United States

and more 50 locations

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: NKTR-214

First Posted Date: 2016-08-16

Last Posted Date: 2021-07-29

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 28

Registration Number: NCT02869295

Locations: 🇺🇸
Investigator Site - Portland, Portland, Oregon, United States
🇺🇸
Investigator Site - New Haven, New Haven, Connecticut, United States
🇺🇸
Investigator Site - Houston, Houston, Texas, United States

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

Phase 3

Completed

Conditions: Low Back Pain
Chronic Pain

Interventions: Drug: NKTR-181 BID tablets

First Posted Date: 2015-02-20

Last Posted Date: 2021-06-22

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 638

Registration Number: NCT02367820

Locations: 🇺🇸
Investigator Site - Stamford, Stamford, Connecticut, United States
🇺🇸
Investigator Site - Tempe, Tempe, Arizona, United States
🇺🇸
Investigator Site - Plantation, Plantation, Florida, United States

and more 53 locations

Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

Phase 3

Completed

Conditions: Chronic Pain
Low Back Pain

Interventions: Drug: Placebo to match NKTR-181 BID tablets
Drug: NKTR-181 BID tablets

First Posted Date: 2015-02-13

Last Posted Date: 2020-09-16

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 1189

Registration Number: NCT02362672

Locations: 🇺🇸
Investigator Site - Little Rock, Little Rock, Arkansas, United States
🇺🇸
Investigator Site - Tempe, Tempe, Arizona, United States
🇺🇸
Investigator Site - Stamford, Stamford, Connecticut, United States

and more 51 locations

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

Interventions: Drug: 50 mg/m2 NKTR 102
Drug: 145 mg/m2 NKTR 102
Drug: 120 mg/m2 NKTR 102

First Posted Date: 2013-11-25

Last Posted Date: 2017-10-06

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 25

Registration Number: NCT01991678

Locations: 🇺🇸
University Hospitals Case-Medical Center Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
USC/LA County, Los Angeles, California, United States

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Phase 1

Completed

Conditions: Advanced Cancer
Metastatic Solid Tumors

Interventions: Drug: NKTR-102

First Posted Date: 2013-11-05

Last Posted Date: 2016-12-22

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 33

Registration Number: NCT01976143

Locations: 🇺🇸
American Institute of Research, Los Angeles, Los Angeles, California, United States
🇺🇸
University Hospitals Case-Medical Center Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Home Terms & Conditions Privacy Policy